<p>Baltic Morning News</p><p> </p><p><strong>Estonian Telecom (Buy) Q4 in-line.</strong> Q4 sales increased by 11.3% y-on-y to EUR 99.1m, slightly above our forecast at EUR 95.3m. Operating profit came in at EUR 25.2m, corresponding to a margin of 25.4% - vs. our expectation of EUR 26.2m and 27.5%, respectively. Pre-tax profit was also in-line at EUR 25.8m, vs. our expectation at EUR 26.6m. Both Fixed-line and Mobile sales came in slightly above our forecast (7.1% and 1.9%, respectively). The growth in mobile was supported by increased volumes of call minutes. Our long-term dividend forecast yield was supported by strong operating cash flow, which amounted to EUR 42m in Q4 (highest this year). Online briefing starts at 11:00 (Estonian time).</p><p><strong>SAF Tehnika Q4.</strong> Sales for Q2/06-07 increased by 6.7% y-on-y to LVL 3.83m, which was in-line with our expectations. However, EBITDA came in at LVL 0.495m - somewhat below our projections. The main reason behind lower than expected profit was the robust increase in salary expenses which, according to the company, was caused by increased production and sales capacities. In addition to higher number of employees, we see tough wage pressure as well. Also, the new high capacity SDH product line has not fully picked up yet.</p><p><strong>Grindeks reports solid Q4.</strong> The Q4 sales came in at LVL 11.52m, equal to a y-o-y growth of 14.1%. Sales to Russia and CIS rose by 18%, and made up 81% of the total sales (Russia 51%, CIS 30%). The Q4 operating profit was LVL 1.70m, equal to a margin of 14.7%. The Q4 pre-tax profit was LVL 1.73m, corresponding to a margin of 15.0%. Grindeks is trading at a PER 2007 of 11.2x with EPS growth of 21%, and it is one of the cheapest stocks in the Baltics. The main sales driver is exposure to rapidly growing Russian pharmaceutical market (+38% in 2006) and the increasing market share (from 0.47% in 2005 to 0.6% in 2006). The main risk is high dependence on its main product, cardiovascular Mildronate, which makes up 73% (2006) of total sales.</p><p><strong>Norma Q4 expected tomorrow.</strong> The Estonian automotive sub-supplier Norma is expected to report Q4 this Thursday (Feb 8th) before market opening. Of our main interest: (1) has AvtoVaz picked up in sales (especially Lada Kalina), (2) how collective Christmas vacation at Autoliv has affected sales to Sweden, (3) comments on the new supply contract with AvtoVaz for 2007.</p><p><strong>Estonia catches Portugal.</strong> According to the CIA's World Factbook 2006, Estonia's estimated GDP per capita (PPP) in 2006 amounted to USD 19,600. Hence, Estonia has passed one of the "old" EU countries Portugal, whose corresponding figure came in at USD 19,100. For Latvia and Lithuania, GDP per capita reached USD 15,400 and USD 15,100, respectively. The figures were USD 31,600 for Sweden, USD 43,500 for USA, and 31,400 for UK.</p>